<DOC>
	<DOC>NCT01207947</DOC>
	<brief_summary>Main object is to investigate the safety profile of Levitra in combination use with alpha-blockers in patients with erectile dysfunction used in clinical practice after launch. In the initial combination date and the first and second observation after initial combination date, number of tablets prescribed, dose of tablets and number of tablets taken until follow-up visit will be investigated. The efficacy and tolerability will be evaluated at 2 months after initial combination date.</brief_summary>
	<brief_title>LEVITRAÂ® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Patients &gt;/= 18 years Enrollment within 7 days after initiation of combination use of Levitra and alphablockers</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Vardenafil</keyword>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Phosphodiesterase Inhibitors</keyword>
	<keyword>Combination use with alpha-blockers</keyword>
</DOC>